Immunic, Inc. (IMUX)
14.23
-0.35
(-2.40%)
USD |
NASDAQ |
Sep 02, 16:00
14.26
+0.03
(+0.21%)
After-Hours: 20:00
Immunic Research and Development Expense (TTM) : 90.64M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 90.64M |
| March 31, 2026 | 86.08M |
| December 31, 2025 | 81.98M |
| September 30, 2025 | 84.53M |
| June 30, 2025 | 85.89M |
| March 31, 2025 | 82.84M |
| December 31, 2024 | 80.05M |
| September 30, 2024 | 77.71M |
| June 30, 2024 | 76.14M |
| March 31, 2024 | 78.99M |
| December 31, 2023 | 83.22M |
| September 30, 2023 | 84.67M |
| June 30, 2023 | 81.41M |
| March 31, 2023 | 76.77M |
| December 31, 2022 | 71.26M |
| September 30, 2022 | 68.90M |
| June 30, 2022 | 67.84M |
| March 31, 2022 | 67.04M |
| December 31, 2021 | 61.12M |
| September 30, 2021 | 53.91M |
| June 30, 2021 | 49.47M |
| March 31, 2021 | 43.72M |
| December 31, 2020 | 38.64M |
| September 30, 2020 | 33.49M |
| June 30, 2020 | 29.55M |
| Date | Value |
|---|---|
| March 31, 2020 | 25.59M |
| December 31, 2019 | 22.51M |
| September 30, 2019 | 20.73M |
| June 30, 2019 | 15.04M |
| March 31, 2019 | 11.17M |
| December 31, 2018 | 17.97M |
| September 30, 2018 | 23.91M |
| June 30, 2018 | 32.19M |
| March 31, 2018 | 39.87M |
| December 31, 2017 | 39.34M |
| September 30, 2017 | 38.01M |
| June 30, 2017 | 35.79M |
| March 31, 2017 | 32.82M |
| December 31, 2016 | 30.05M |
| September 30, 2016 | 28.01M |
| June 30, 2016 | 29.51M |
| March 31, 2016 | 34.20M |
| December 31, 2015 | 39.09M |
| September 30, 2015 | 43.15M |
| June 30, 2015 | 44.43M |
| March 31, 2015 | 42.01M |
| December 31, 2014 | 39.48M |
| September 30, 2014 | 36.24M |
| June 30, 2014 | 32.16M |
| March 31, 2014 | 27.57M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Sionna Therapeutics, Inc. | 72.04M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |
| Savara, Inc. | 86.84M |